The AKT inhibitor, LY294002, was used to characterize the IL-17B-activated AKT/β-catenin pathway in gastric cancer cells, and western blotting was used to measure the expression of β-catenin and stemness-related genes treated with or without exogenous rIL-17B. This evidence concerns the gene AKT1 and gastric cancer.